Suzlon Energy gets 21 MW order from Serum Institute

ADVERTISEMENT

A press release from Suzlon said the project comprises 10 units of its S88 2.1MW wind turbine generators and will be commissioned in Maharashtra for captive consumption.

 

Serum Institute has an existing 39 MW installed wind power base with Suzlon in Maharashtra. This new project takes Serum’s renewable energy portfolio to 60 MW. 

 

Under the agreement, Suzlon will supply, set up, operate, and maintain the wind turbines for Serum Institute of India.

 

Dr. Cyrus Poonawalla, Chairman, Serum Institute of India said: “As an organization we are committed to the conservation of the environment and are constantly seeking ways to reduce the carbon footprint from our business operations. We see wind as a smart option with its techno-economic maturity and comparatively lower risks. The main criteria for us when choosing a partner in such a project is technological expertise, as well as proven market capabilities and Suzlon meets that criteria. We are very pleased to be partnering with them on yet another wind project.”

 

 Mr. Tulsi Tanti, Chairman, Suzlon Group, said: “We are very pleased to welcome this repeat order from Serum Institute of India. In times when the future of our planet is being discussed in various forums, it is reassuring to see businesses proactively taking steps to offset their carbon emissions. At Suzlon we provide flexible business models to cater to various customer needs. We look forward to building more successful wind power projects with Serum Institute of India.”

 

Serum Institute of India is India's top biotech company and is among the world's largest makers of pediatric vaccines. It has also established itself as the world's largest producer of Measles and DTP group of vaccines. The company was founded in 1966 with the aim of manufacturing life-saving immune-biologicals, which were in shortage in the country and had to be imported at high prices.

 

NNN

ADVERTISEMENT